Drug intelligence / Profile preview

SBT-100

Development stage: Unknown
Lead developer: Singh Biotechnology
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

SBT-100 is a cell-penetrating single-domain antibody (sdAb) from Singh Biotechnology that binds KRAS and inhibits growth of human cancers with KRAS activating mutations (AACR 2019 abstract 1544, Cancer Research 79(13 Suppl)). Corrected from a record attributing it to Sonnet BioTherapeutics; see pipeline issue #959.

Other names: SON-101SON101SON 101

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)STAT1 (Signal transducer and activator of transcription protein 1)KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on SBT-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBT-100.

Explore the full profile